CENTER VALLEY, Pa. , June 4, 2025 /PRNewswire/ -- Aesculap, Inc. (Aesculap), the world's largest manufacturer of surgical instruments known for its innovations in neurosurgery, power systems and visualization, has launched XABO ® Antibiotic-Impregnated Catheters in the U.S. market which will help to significantly reduce the risk of shunt infections in hydrocephalus patients. 1 This innovative product is designed to improve treatment for both pediatric and adult patients who suffer from this condition.

Hydrocephalus, characterized by excessive cerebrospinal fluid in the brain, affects over 1 million people in the United States . Shunt therapy, the most common treatment, 2 often comes with the risk of infection, 3 which impacts 7-15% of patients. 4 These infections can imp

See Full Page